Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomised trial (Q39499728)

12 September 2017

Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomised trial (English)

1 reference

12 September 2017

1 reference

1 reference

L Sagliocca

1

1 reference

12 September 2017

P Amoroso

2

1 reference

12 September 2017

T Stroffolini

3

1 reference

12 September 2017

B Adamo

4

1 reference

12 September 2017

M E Tosti

5

1 reference

12 September 2017

G Lettieri

6

1 reference

12 September 2017

C Esposito

7

1 reference

12 September 2017

S Buonocore

8

1 reference

12 September 2017

P Pierri

9

1 reference

12 September 2017

A Mele

10

1 reference

12 September 2017

language of work or name

English

0 references

publication date

1 April 1999

1 reference

12 September 2017

1 reference

12 September 2017

353

1 reference

12 September 2017

9159

1 reference

12 September 2017

1136-1139

1 reference

Incidence of and risk factors for hepatitis A in Italy: public health indications from a 10-year surveillance. SEIEVA Collaborating Group

12 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2908139-2

7 January 2021

Worldwide epidemiology of hepatitis A virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2908139-2

7 January 2021

Frequency of illness associated with epidemic hepatitis A virus infections in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2908139-2

7 January 2021

Recurrent epidemic hepatitis A associated with consumption of raw shellfish, probably controlled through public health measures.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2908139-2

7 January 2021

An outbreak of hepatitis A in young adults in central Italy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2908139-2

7 January 2021

Immunoglobulin prophylaxis for hepatitis A

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2908139-2

7 January 2021

Specific anti-HAV immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2908139-2

7 January 2021

A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2908139-2

7 January 2021

Effect of postexposure vaccination in a chimpanzee model of hepatitis A virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2908139-2

7 January 2021

Interruption of an outbreak of hepatitis A in two villages by vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2908139-2

7 January 2021

A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2908139-2

7 January 2021

Intrafamilial clustering of hepatitis A

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2908139-2

7 January 2021

Understanding clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2908139-2

7 January 2021

Hepatitis A vaccine. A new convenient single-dose schedule with booster when long-term immunization is warranted

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2908139-2

7 January 2021

10.1016/S0140-6736(98)08139-2

Identifiers

DOI

1 reference

release_2itzaflx7bf45hi3fk73h65moa

12 September 2017

0 references

1 reference